HalioDx, NanoString develop gene expression assays for immunotherapies
Molecular diagnostic firms HalioDx SAS and NanoString Technologies Inc. will collaborate on the development of gene expression assays to evaluate patient response to immunotherapeutics.
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.